Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy.

Sinha S, Dwivedi N, Tao S, Jamadar A, Kakade VR, Neil MO, Weiss RH, Enders J, Calvet JP, Thomas SM, Rao R.

Oncogene. 2019 Oct 15. doi: 10.1038/s41388-019-1059-0. [Epub ahead of print]

PMID:
31616061
2.

Metanephric organ culture.

Maser RL, Magenheimer BS, Calvet JP.

Methods Cell Biol. 2019;153:169-183. doi: 10.1016/bs.mcb.2019.04.018. Epub 2019 Jun 13.

PMID:
31395378
3.

Human-Specific Abnormal Alternative Splicing of Wild-Type PKD1 Induces Premature Termination of Polycystin-1.

Lea WA, Parnell SC, Wallace DP, Calvet JP, Zelenchuk LV, Alvarez NS, Ward CJ.

J Am Soc Nephrol. 2018 Oct;29(10):2482-2492. doi: 10.1681/ASN.2018040442. Epub 2018 Sep 5.

4.

A mutation affecting polycystin-1 mediated heterotrimeric G-protein signaling causes PKD.

Parnell SC, Magenheimer BS, Maser RL, Pavlov TS, Havens MA, Hastings ML, Jackson SF, Ward CJ, Peterson KR, Staruschenko A, Calvet JP.

Hum Mol Genet. 2018 Oct 1;27(19):3313-3324. doi: 10.1093/hmg/ddy223.

5.

Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.

Li LX, Zhou JX, Calvet JP, Godwin AK, Jensen RA, Li X.

Cell Death Dis. 2018 Feb 27;9(3):326. doi: 10.1038/s41419-018-0347-x.

6.

Aberrant Regulation of Notch3 Signaling Pathway in Polycystic Kidney Disease.

Idowu J, Home T, Patel N, Magenheimer B, Tran PV, Maser RL, Ward CJ, Calvet JP, Wallace DP, Sharma M.

Sci Rep. 2018 Feb 20;8(1):3340. doi: 10.1038/s41598-018-21132-3.

7.

Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.

Li LX, Fan LX, Zhou JX, Grantham JJ, Calvet JP, Sage J, Li X.

J Clin Invest. 2017 Jun 30;127(7):2751-2764. doi: 10.1172/JCI90921. Epub 2017 Jun 12.

8.

Integrin-Linked Kinase Signaling Promotes Cyst Growth and Fibrosis in Polycystic Kidney Disease.

Raman A, Reif GA, Dai Y, Khanna A, Li X, Astleford L, Parnell SC, Calvet JP, Wallace DP.

J Am Soc Nephrol. 2017 Sep;28(9):2708-2719. doi: 10.1681/ASN.2016111235. Epub 2017 May 18.

9.

A One Health overview, facilitating advances in comparative medicine and translational research.

Stroud C, Dmitriev I, Kashentseva E, Bryan JN, Curiel DT, Rindt H, Reinero C, Henry CJ, Bergman PJ, Mason NJ, Gnanandarajah JS, Engiles JB, Gray F, Laughlin D, Gaurnier-Hausser A, Wallecha A, Huebner M, Paterson Y, O'Connor D, Treml LS, Stannard JP, Cook JL, Jacobs M, Wyckoff GJ, Likins L, Sabbagh U, Skaff A, Guloy AS, Hays HD, LeBlanc AK, Coates JR, Katz ML, Lyons LA, Johnson GC, Johnson GS, O'Brien DP, Duan D, Calvet JP, Gandolfi B, Baron DA, Weiss ML, Webster DA, Karanu FN, Robb EJ, Harman RJ.

Clin Transl Med. 2016 Aug;5(Suppl 1):26. doi: 10.1186/s40169-016-0107-4.

10.

The Role of Calcium and Cyclic AMP in PKD.

Calvet JP.

In: Li X, editor. Polycystic Kidney Disease [Internet]. Brisbane (AU): Codon Publications; 2015 Nov. Chapter 8.

11.

A cAMP and CREB-mediated feed-forward mechanism regulates GSK3β in polycystic kidney disease.

Kakade VR, Tao S, Rajagopal M, Zhou X, Li X, Yu AS, Calvet JP, Pandey P, Rao R.

J Mol Cell Biol. 2016 Dec;8(6):464-476. Epub 2016 May 4.

12.

Phosphodiesterase Isoform Regulation of Cell Proliferation and Fluid Secretion in Autosomal Dominant Polycystic Kidney Disease.

Pinto CS, Raman A, Reif GA, Magenheimer BS, White C, Calvet JP, Wallace DP.

J Am Soc Nephrol. 2016 Apr;27(4):1124-34. doi: 10.1681/ASN.2015010047. Epub 2015 Aug 19.

13.

Ouabain Regulates CFTR-Mediated Anion Secretion and Na,K-ATPase Transport in ADPKD Cells.

Jansson K, Venugopal J, Sánchez G, Magenheimer BS, Reif GA, Wallace DP, Calvet JP, Blanco G.

J Membr Biol. 2015 Dec;248(6):1145-57. doi: 10.1007/s00232-015-9832-7. Epub 2015 Aug 20.

14.

TNFα signaling regulates cystic epithelial cell proliferation through Akt/mTOR and ERK/MAPK/Cdk2 mediated Id2 signaling.

Zhou JX, Fan LX, Li X, Calvet JP, Li X.

PLoS One. 2015 Jun 25;10(6):e0131043. doi: 10.1371/journal.pone.0131043. eCollection 2015.

15.

Nuclear Localization Signal and p53 Binding Site in MAP/ERK Kinase Kinase 1 (MEKK1).

Chipps E, Protzman A, Muhi MZ, Ando S, Calvet JP, Islam MR.

J Cell Biochem. 2015 Dec;116(12):2903-14. doi: 10.1002/jcb.25238.

16.

The Future of Polycystic Kidney Disease Research--As Seen By the 12 Kaplan Awardees.

Antignac C, Calvet JP, Germino GG, Grantham JJ, Guay-Woodford LM, Harris PC, Hildebrandt F, Peters DJ, Somlo S, Torres VE, Walz G, Zhou J, Yu AS.

J Am Soc Nephrol. 2015 Sep;26(9):2081-95. doi: 10.1681/ASN.2014121192. Epub 2015 May 7.

17.

Renal MODY-fier genes.

Calvet JP.

Am J Physiol Renal Physiol. 2014 Sep 15;307(6):F656-7. doi: 10.1152/ajprenal.00377.2014. Epub 2014 Jul 23. No abstract available.

18.

Developmental signaling: does it bridge the gap between cilia dysfunction and renal cystogenesis?

Tran PV, Sharma M, Li X, Calvet JP.

Birth Defects Res C Embryo Today. 2014 Jun;102(2):159-73. doi: 10.1002/bdrc.21065. Epub 2014 May 26. Review.

19.

Polycystic kidney disease and cancer after renal transplantation.

Wetmore JB, Calvet JP, Yu AS, Lynch CF, Wang CJ, Kasiske BL, Engels EA.

J Am Soc Nephrol. 2014 Oct;25(10):2335-41. doi: 10.1681/ASN.2013101122. Epub 2014 May 22.

20.

SIRT2 regulates ciliogenesis and contributes to abnormal centrosome amplification caused by loss of polycystin-1.

Zhou X, Fan LX, Li K, Ramchandran R, Calvet JP, Li X.

Hum Mol Genet. 2014 Mar 15;23(6):1644-55. doi: 10.1093/hmg/ddt556. Epub 2013 Nov 7.

21.

Overexpression of the polycystin-1 C-tail enhances sensitivity of M-1 cells to ouabain.

Jansson K, Magenheimer BS, Maser RL, Calvet JP, Blanco G.

J Membr Biol. 2013 Jul;246(7):581-90. doi: 10.1007/s00232-013-9573-4. Epub 2013 Jun 20.

22.

Endogenous concentrations of ouabain act as a cofactor to stimulate fluid secretion and cyst growth of in vitro ADPKD models via cAMP and EGFR-Src-MEK pathways.

Jansson K, Nguyen AN, Magenheimer BS, Reif GA, Aramadhaka LR, Bello-Reuss E, Wallace DP, Calvet JP, Blanco G.

Am J Physiol Renal Physiol. 2012 Oct;303(7):F982-90. doi: 10.1152/ajprenal.00677.2011. Epub 2012 Aug 1.

23.

Protein phosphatase-1α interacts with and dephosphorylates polycystin-1.

Parnell SC, Puri S, Wallace DP, Calvet JP.

PLoS One. 2012;7(6):e36798. doi: 10.1371/journal.pone.0036798. Epub 2012 Jun 4.

24.

Global Gene Expression Profiling in PPAR-γ Agonist-Treated Kidneys in an Orthologous Rat Model of Human Autosomal Recessive Polycystic Kidney Disease.

Yoshihara D, Kugita M, Yamaguchi T, Aukema HM, Kurahashi H, Morita M, Hiki Y, Calvet JP, Wallace DP, Toyohara T, Abe T, Nagao S.

PPAR Res. 2012;2012:695898. doi: 10.1155/2012/695898. Epub 2012 May 13.

25.

Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation.

Fan LX, Li X, Magenheimer B, Calvet JP, Li X.

Kidney Int. 2012 Jan;81(1):76-85. doi: 10.1038/ki.2011.296. Epub 2011 Sep 7.

26.

PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.

Yoshihara D, Kurahashi H, Morita M, Kugita M, Hiki Y, Aukema HM, Yamaguchi T, Calvet JP, Wallace DP, Nagao S.

Am J Physiol Renal Physiol. 2011 Feb;300(2):F465-74. doi: 10.1152/ajprenal.00460.2010. Epub 2010 Dec 8.

27.

Global gene expression profiling in early-stage polycystic kidney disease in the Han:SPRD Cy rat identifies a role for RXR signaling.

Kugita M, Nishii K, Morita M, Yoshihara D, Kowa-Sugiyama H, Yamada K, Yamaguchi T, Wallace DP, Calvet JP, Kurahashi H, Nagao S.

Am J Physiol Renal Physiol. 2011 Jan;300(1):F177-88. doi: 10.1152/ajprenal.00470.2010. Epub 2010 Oct 6.

28.

MAP/ERK kinase kinase 1 (MEKK1) mediates transcriptional repression by interacting with polycystic kidney disease-1 (PKD1) promoter-bound p53 tumor suppressor protein.

Islam MR, Jimenez T, Pelham C, Rodova M, Puri S, Magenheimer BS, Maser RL, Widmann C, Calvet JP.

J Biol Chem. 2010 Dec 10;285(50):38818-31. doi: 10.1074/jbc.M110.145284. Epub 2010 Oct 5.

29.

Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells.

Yamaguchi T, Reif GA, Calvet JP, Wallace DP.

Am J Physiol Renal Physiol. 2010 Nov;299(5):F944-51. doi: 10.1152/ajprenal.00387.2010. Epub 2010 Sep 1.

30.

Polycystic kidney disease in Han:SPRD Cy rats is associated with elevated expression and mislocalization of SamCystin.

Nagao S, Morita M, Kugita M, Yoshihara D, Yamaguchi T, Kurahashi H, Calvet JP, Wallace DP.

Am J Physiol Renal Physiol. 2010 Nov;299(5):F1078-86. doi: 10.1152/ajprenal.00504.2009. Epub 2010 Aug 18.

31.

Strategies for folding of affinity tagged proteins using GroEL and osmolytes.

Katayama H, McGill M, Kearns A, Brzozowski M, Degner N, Harnett B, Kornilayev B, Matković-Calogović D, Holyoak T, Calvet JP, Gogol EP, Seed J, Fisher MT.

J Struct Funct Genomics. 2009 Mar;10(1):57-66. doi: 10.1007/s10969-008-9053-8. Epub 2008 Dec 12.

32.

Retinoic acid-dependent activation of the polycystic kidney disease-1 (PKD1) promoter.

Islam MR, Puri S, Rodova M, Magenheimer BS, Maser RL, Calvet JP.

Am J Physiol Renal Physiol. 2008 Dec;295(6):F1845-54. doi: 10.1152/ajprenal.90355.2008. Epub 2008 Oct 15.

33.

A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease.

Li X, Magenheimer BS, Xia S, Johnson T, Wallace DP, Calvet JP, Li R.

Nat Med. 2008 Aug;14(8):863-8. doi: 10.1038/nm1783. Epub 2008 Jun 15.

34.

Strategies to inhibit cyst formation in ADPKD.

Calvet JP.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1205-11. doi: 10.2215/CJN.05651207. Epub 2008 Apr 23.

35.

Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy/+ rat.

Nagao S, Nishii K, Yoshihara D, Kurahashi H, Nagaoka K, Yamashita T, Takahashi H, Yamaguchi T, Calvet JP, Wallace DP.

Kidney Int. 2008 Feb;73(3):269-77. Epub 2007 Oct 17.

36.

Early embryonic renal tubules of wild-type and polycystic kidney disease kidneys respond to cAMP stimulation with cystic fibrosis transmembrane conductance regulator/Na(+),K(+),2Cl(-) Co-transporter-dependent cystic dilation.

Magenheimer BS, St John PL, Isom KS, Abrahamson DR, De Lisle RC, Wallace DP, Maser RL, Grantham JJ, Calvet JP.

J Am Soc Nephrol. 2006 Dec;17(12):3424-37. Epub 2006 Nov 15.

37.

The polycystic kidney disease-1 gene is a target for p53-mediated transcriptional repression.

Van Bodegom D, Saifudeen Z, Dipp S, Puri S, Magenheimer BS, Calvet JP, El-Dahr SS.

J Biol Chem. 2006 Oct 20;281(42):31234-44. Epub 2006 Aug 24.

38.

Cilia-like structures and polycystin-1 in osteoblasts/osteocytes and associated abnormalities in skeletogenesis and Runx2 expression.

Xiao Z, Zhang S, Mahlios J, Zhou G, Magenheimer BS, Guo D, Dallas SL, Maser R, Calvet JP, Bonewald L, Quarles LD.

J Biol Chem. 2006 Oct 13;281(41):30884-95. Epub 2006 Aug 11.

39.

MEK inhibition holds promise for polycystic kidney disease.

Calvet JP.

J Am Soc Nephrol. 2006 Jun;17(6):1498-500. Epub 2006 May 10. No abstract available.

40.

Ets factors regulate the polycystic kidney disease-1 promoter.

Puri S, Rodova M, Islam MR, Magenheimer BS, Maser RL, Calvet JP.

Biochem Biophys Res Commun. 2006 Apr 21;342(4):1005-13. Epub 2006 Feb 20.

PMID:
16510125
41.

Polycystin-1 activates the calcineurin/NFAT (nuclear factor of activated T-cells) signaling pathway.

Puri S, Magenheimer BS, Maser RL, Ryan EM, Zien CA, Walker DD, Wallace DP, Hempson SJ, Calvet JP.

J Biol Chem. 2004 Dec 31;279(53):55455-64. Epub 2004 Oct 5.

42.

Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype.

Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP.

J Biol Chem. 2004 Sep 24;279(39):40419-30. Epub 2004 Jul 19.

43.

Aberrant polycystin-1 expression results in modification of activator protein-1 activity, whereas Wnt signaling remains unaffected.

Le NH, van der Bent P, Huls G, van de Wetering M, Loghman-Adham M, Ong AC, Calvet JP, Clevers H, Breuning MH, van Dam H, Peters DJ.

J Biol Chem. 2004 Jun 25;279(26):27472-81. Epub 2004 Apr 15.

44.

Transient transfection assays for analysis of signal transduction in renal cells.

Maser RL, Magenheimer BS, Zien CA, Calvet JP.

Methods Mol Med. 2003;86:205-17. No abstract available.

PMID:
12886771
45.

Remarkable sequence conservation of the last intron in the PKD1 gene.

Rodova M, Islam MR, Peterson KR, Calvet JP.

Mol Biol Evol. 2003 Oct;20(10):1669-74. Epub 2003 Jun 27.

PMID:
12832634
46.

New insights into ciliary function: kidney cysts and photoreceptors.

Calvet JP.

Proc Natl Acad Sci U S A. 2003 May 13;100(10):5583-5. Epub 2003 May 5. No abstract available.

47.

Ciliary signaling goes down the tubes.

Calvet JP.

Nat Genet. 2003 Feb;33(2):113-4. Epub 2003 Jan 6. No abstract available.

PMID:
12514736
48.

Cilia in PKD--letting it all hang out.

Calvet JP.

J Am Soc Nephrol. 2002 Oct;13(10):2614-6. Review. No abstract available.

49.

The polycystic kidney disease-1 promoter is a target of the beta-catenin/T-cell factor pathway.

Rodova M, Islam MR, Maser RL, Calvet JP.

J Biol Chem. 2002 Aug 16;277(33):29577-83. Epub 2002 Jun 4.

50.

Acetylation of beta-catenin by CREB-binding protein (CBP).

Wolf D, Rodova M, Miska EA, Calvet JP, Kouzarides T.

J Biol Chem. 2002 Jul 12;277(28):25562-7. Epub 2002 Apr 24.

Supplemental Content

Loading ...
Support Center